Introduction
Despite an abundance of candidate drugs and targets, the past decade has seen a decline in the number of novel therapeutics reaching the clinic. This widening translational gap has driven significant investment in infrastructure and realignment of grant funding allowing the field of translational research to generate enormous momentum over the past 5 years. Indeed, patients and clinicians within specialties such as cardiology, oncology and rheumatology are beginning to benefit from improved 'bench to bedside' science through earlier and more accurate detection of disease and more efficacious, targeted therapies. Critical care, however, is a comparatively young specialty with an emerging and evolving research profile. Despite millions of pounds of investment in basic science and time-consuming clinical trials, the majority of pharmacological interventions developed for critical illness have not translated into measurable clinical benefit. There is therefore a significant and unmet need for highquality translational research in critical care, which is arguably as great as any other medical specialty. Here, we review recent developments in translational research in the fields of acute lung injury (ALI), acute kidney injury (AKI) and sepsis with a focus on emerging biomarkers.
What is translational medicine?
Translational research can be defined as the process by which advances and innovations in basic science are incorporated into the clinic; concepts taken from the laboratory are bridged to early-phase clinical trials involving small numbers of patients, through collaboration between scientists and clinicians. Increasingly, translational research also demands collaboration with industry with the associated benefits of shared expertise, infrastructure and funding. When possible, humans, human tissues or human data, as opposed to animals, are used to optimize the validity and reliability of data generated.
Purpose of review
In this article, we review recent developments in translational research in the fields of acute lung injury, acute kidney injury and sepsis with a focus on emerging biomarkers and outline future advances in the field.
Recent findings
There is currently a significant and unmet need for high quality translational research in critical care. The emergence of '-omics' technologies and sophisticated imaging techniques have resulted in a rapid growth of emerging biomarkers. Biomarkers would ideally provide early and reliable endpoints for proof of concept in clinical trials and inform clinical decision making through earlier and more precise diagnosis and risk stratification. Summary Despite significant investment in basic science and time-consuming clinical trials, the majority of pharmacological interventions developed for critical illness have yet to translate into measurable clinical benefit. Future validation and qualification of emerging biomarkers allied to advances in pharmacogenomic profiling have the potential to provide valuable clinical information while accurately phenotyping patients enrolled in future clinical trials. into a specific pathway of interest (Fig. 1) . Indeed, much current translational research involves the interrogation of biological samples (e.g. blood, urine, tissue) stored in institutionally owned or commercial biobanks for novel markers of disease. The search for biomarkers has become one of the pillars of translational research. A biomarker is defined as a characteristic that can be objectively measured and evaluated as an indicator of normal biological or pathogenic processes, or pharmacological responses to a therapeutic intervention [1] .
Keywords
The proposed value of biomarkers is primarily in providing early, reliable proof of concept, thus limiting costly, late-phase attrition of clinical trials. Secondary applications include informed clinical decision-making through earlier (and more precise) diagnosis, accurate phenotyping of patients to create tighter trial populations, monitoring of treatment response and improved risk stratification. An exemplar biomarker in critical care would be biologically plausible, sensitive, and highly specific, adding prognostic information independent of existing systems, whilst at the same time being readily and safely acquired from a critically ill patient in the setting of an intensive care unit (Fig. 2) [2].
The search for biomarkers has been associated with an explosion in the application of high throughput '-omics' technologies including genomics, proteomics, transcriptomics and metabonomics ( Fig. 3) and novel imaging modalities such as positron emission tomography (PET) and functional magnetic resonance imaging (fMRI); newly discovered genes, proteins, and pathways can not only function as biomarkers but can also represent powerful new drug targets. To date, few biomarkers have been developed to the point of regulatory usefulness; all markers must endure validation (have known characteristics, be well standardized and accurate) and qualification (be integral to disease pathogenesis and clinical endpoints) [3] .
Why is translational research important?
Despite massive investment and many multicentre trials, few disease-modifying therapies have reached the critically ill patient. The reasons for these shortcomings are multifactorial and relate to failings at both the bench and the bedside. Preclinical animal models are simplistic and translate poorly to human disease owing to insurmountable species differences in pathophysiology and challenges providing supportive care to animals with severe physiological derangements. Clinical trials in critical care are ethically and logistically challenging, hampered by difficulties recruiting and phenotyping patients with syndromes such as ALI, which represent a heterogeneous Proof of mechanism studies in vivo or in ex-vivo human models Novel imaging techniques such as PET receptor occupancy studies Proof-of-concept studies in humans Drug development from bench to bedside involves target identification using high throughput '-omics' technologies in human tissues. Proof-ofmechanism studies confirm the optimal drug targets with validation of efficacy in early human studies.
group of primary pathologies. Methods to improve the translation of basic science in to effective therapies, is therefore desperately needed.
Emerging investigative tools are beginning to generate unique and exciting human in-vitro, ex-vivo and in-vivo data, providing unique mechanistic insight and generating novel therapeutic targets. Despite the obvious benefits, critical care researchers have only recently begun to embrace translational science and its methodologies.
Beyond drug development, critical care suffers from a lack of predictability and reliability in clinical phenotyping. As a result a consensus approach for monitoring and treatment of individual patients is often lacking. In addition, there is established evidence that rapid diagnosis and early intervention are key determinants of outcome in critical illness [4] [5] [6] . Robust biomarkers allowing earlier and more precise diagnosis as well as prognostic markers, analogous to the use of troponins in cardiology, would be a major advance in patient care.
Acute lung injury
Numerous studies of putative biomarkers in ALI have demonstrated a lack of superiority over routine clinical markers [7] . Recognizing that no single clinical or biologic marker is likely to prognosticate reliably in the complex syndrome of ALI, combining a panel of eight plasma biomarkers and clinical predictors was superior to either alone for predicting mortality in 528 ALI/acute respiratory distress syndrome (ARDS) patients enrolled in the ARDS Network ALVEOLI study [8 ] . Receiveroperating curves were used to assess four models of mortality; clinical predictors alone, biomarker predictors alone Genomic analysis in ALI has been hampered by the heterogeneity of the clinical phenotype and the influences of environmental factors. However, in a two-stage case-control study followed by a nested case-control design in healthy volunteers (n ¼ 294) and patients with ALI (n ¼ 324) from the ARDS Network FACTT study, the commonly occurring FAS haplotype was associated with ALI susceptibility (P ¼ 0.05) [9 ] . Activation of the Fas(TNF receptor superfamily, member 6) pathway induces an intracellular cascade culminating in inflammation and apoptosis of Fas-bearing cells; dysregulation of the gene coding for Fas, FAS, has therefore been implicated as potential contributor to the alveolar epithelial cell inflammation and apoptosis observed in clinical ALI [10, 11] . No association between FAS genotypes and mortality was observed, suggesting that genetic variation in FAS primarily influences susceptibility to ALI as opposed to severity [9 ] .
The role of quantitative metabonomics as an emerging tool for biomarker discovery in sepsis-induced ALI was investigated using quantitative 1H-NMR-spectroscopy
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Properties of the ideal biomarker in critical illness
•Has biological plausibility in terms of its role in the pathogenesis of disease •Highly sensitive and specific •Associated with a clinically important outcome such as mortality •Modified by an effective intervention to change the target outcome of interest •Measurement is safely, easily and reproducibly acquired in the critically ill
Modified from Bucher et al. [2] .
Figure 3 The comparative strengths of industry and academia in translational research
Industry academia to analyse plasma samples from 13 patients with sepsisinduced ALI or ARDS and six control individuals [12 ] . Differences between ALI patients and healthy individuals were found in total glutathione, adenosine, phosphatidylserine and sphingomyelin. Moreover, myoinositol levels were associated with acute physiology scores (APS) and ventilator-free days. There was also an association between total glutathione and APS. More studies in larger sample sizes are required to determine the significance of these findings in a wider patient population.
The issue of interspecies variability was highlighted by comparative proteomic analysis between pooled broncho-alveolar lavage fluid (BALF) from patients with and murine models of ALI, which identified only 21 homologous proteins [13 ] . Significant functional differences in the BALF proteome were reported, most prominently in the selective enrichment of oxidative stress pathways in mice. Given that current animal models are unable to recapitulate the complex pathophysiological changes seen in patients, over the past 2 years researchers have begun using human ex-vivo and in-vivo models of ALI. Using an ex-vivo perfused human lung model, investigators from University of California San Francisco [14 ] induced ALI with an intra-bronchial instillation of (0.1 mg/kg) of Escherichia coli endotoxin. This resulted in acute pulmonary oedema, an increase in lung vascular permeability and an almost complete loss of alveolar fluid clearance (AFC). These effects were associated with a statistically significant increase in airspace neutrophilic infiltration and BALF levels of pro-inflammatory cytokines IL-1b, TNF-a and IL-8. Instillation of mesenchymal stem cells reduced endotoxin-induced injury and inflammation and augmented AFC compared to controls, their effect being abolished by pretreatment with keratinocyte growth factor siRNA.
The value of in-vivo human models of ventilator-induced lung injury (VILI) was recently demonstrated. In 30 patients undergoing lung resection for lung cancer, one lung ventilation (OLV) was used to investigate potential exhaled breath condensate (EBC) and plasma biomarkers of VILI [15 ] . Of note, EBC pH was reduced early and persistently during OLV suggesting that, as a direct means of sampling the milieu of the lung, it may hold promise as a noninvasive real-time biomarker of VILI.
Acute kidney injury
The search for biomarkers in AKI has gathered enormous momentum in recent years; the current gold standard diagnostic test of a temporal change in serum creatinine is both inaccurate and measurement involves an inherent diagnostic delay. Moreover, there is an absence of therapeutic options beyond renal replacement therapy (RRT). Multiple candidates have been proposed, although the validation process for the majority remains in its infancy [16 ] . Biomarkers are sought to aid the earlier diagnosis of AKI as well as risk stratification, including requirement for RRT and prediction of renal recovery.
During recent years neutrophil gelatinase-associated lipocalin (NGAL) has emerged as the most promising early marker of AKI [17] . Serum NGAL was recently shown in more than 300 patients to predict AKI at least 24 h earlier than the risk, injury, failure, loss, and endstage kidney (RIFLE) criteria in a mixed intensive care unit (ICU) population (n ¼ 301) [18 ] . Whereas a recent meta-analysis suggested that serum and urine NGAL levels perform equally well [17] , significantly higher serum compared to urine NGAL values in patients suffering from sepsis-associated AKI as compared with nonseptic AKI (n ¼ 83) were recently reported [19 ] . Moreover, in 45 patients, plasma NGAL levels were not significantly different between septic shock patients with and without AKI [20 ] . Urinary NGAL may therefore be a more reliable marker of AKI than plasma NGAL.
Angiopoietin-2 is a growth factor that promotes angiogenesis. Plasma concentrations were associated with increased mortality in sepsis, and predicted 28-day survival in 117 critically ill patients requiring RRT [21 ] . Using plasma and urine samples from the largest biomarker study to date (n ¼ 529) [22 ] , the first head to head comparison of six biomarkers in AKI was reported [23 ] . On ICU entry, no biomarker accurately diagnosed or predicted AKI, whereas NGAL, cystatin C, and IL-18 predicted the need for RRT. Performance was improved by stratification for baseline estimated glomerular filtration rate or time or both.
Several novel imaging techniques, such as bloodoxygen-level-dependent MRI (which assesses renal oxygen bioavailability), and multiphoton microscopy (which facilitates direct visualization and integration of structure and function of the kidneys) are emerging and may allow correlation between structure and function [24 ,25 ] . However, their utility in humans with AKI, at present, is uncertain. Meanwhile, a Doppler ultrasonography-derived renal resistive index (a measure of resistance to blood flow) has shown promise as a discriminator between transient and sustained AKI in 51 critically ill patients [26 ] . The ability of the resistive index to discriminate persistent AKI was excellent (AUC 0.91). A resistive index above 0.795 was associated with a sensitivity and specificity of 82 and 92%, respectively, for predicting persistent AKI.
Sepsis
Whereas multiple candidate biomarkers have been investigated, 178 candidates evaluated in 3370 studies [27 ] , their clinical utility in sepsis has been limited. Sepsis is a complex, rapidly evolving, and incompletely understood syndrome whose outcome is influenced by the host inflammatory response, as well as genetic and environmental factors. Thus, it is improbable that a single biomarker, let alone a single measurement of a biomarker, will distinguish infection from sterile inflammation. Whereas panels of biomarkers may offer a potential solution, an alternative approach is the validation of biomarkers that target a precise mechanism or guide clinical management; the emerging application of procalcitonin (PCT), a calcitonin precursor hormone, is one such example.
As a diagnostic marker of sepsis, there remains debate regarding the specificity of PCT [28, 29] . As a prognostic marker, a recent study investigated PCT in 242 intensive care patients with a clinical diagnosis of severe sepsis and septic shock [30 ] . Patients with proven bacteraemia and shocked patients had higher PCT levels (P < 0.001 and P ¼ 0.02, respectively) but, contrary to a previous study [31] , levels did not differentiate survivors from nonsurvivors. There was, however, an association between a temporal decrease in PCT levels of more than 50% in the first 72 h of admission and mortality (P ¼ 0.007). The emerging role of PCT to guide antibiotic stewardship on the ICU was further enhanced by a multicentre, prospective, parallel-group study of a PCTbased algorithm for initiation of antibiotics and duration of antibiotic therapy in 621 intensive care patients with suspected bacterial infection [32 ] . PCT-guided antibiotic therapy was associated with a 23% relative reduction in antibiotic exposure (P < 0.0001) with no significant increase in 28-day or 60-day mortality. Interestingly, despite lower antibiotic exposure in the PCT group there was no reduction in the rates of emerging multidrug-resistant bacteria in this group.
Alternative emerging mechanistic targets include the F2-isoprostanes and isofurans as markers of oxidative stress. These lipid peroxidation products were associated with renal, hepatic, and coagulation failure but not with circulatory or pulmonary failure in 50 patients with severe sepsis [33 ] . Similarly a significant correlation between the plasma levels of thioredoxin and macrophage inhibitory factor (MIF) was demonstrated in 32 patients with systemic inflammatory response syndrome (SIRS)/sepsis [34 ] .
The application of proteomics in the search for diagnostic markers in sepsis is still in its infancy. In a prospective study of 61 patients who underwent liver transplantation [35 ] , proteomic analysis of day 5 plasma samples revealed expression of five protein peaks with significant differences in patients with and without sepsis. Although the proteins were not identified, this technology may offer an interesting alternative to PCT or C-reactive protein (CRP).
The impact of the CysGlyGln haplotype of the b2-adrenergic receptor gene (ADRB2) [36 ] , which has been associated with altered responses to adrenergic agonists on outcome in septic shock, was recently reported. Homozygotes for the CysGlyGln haplotype, required higher norepinephrine dose over days 1-3, had higher heart rates, developed more organ dysfunction, and had an increased 28-day mortality in the two cohorts studied (n ¼ 1215) [36 ] . The same cohort of patients was used to genotype 59 single-nucleotide polymorphisms in the nuclear factor-kB (NF-kB) pathway. Those patients of the CC genotype of NIK rs7222094 had significantly increased mortality. The CC genotype was associated with mRNA expression of CXCL10 (a chemokine regulated by NF-kB) in vitro, whereas plasma levels of CXCL10 were also significantly lower (P ¼ 0.017). Polymorphisms of NIK could therefore act as a prognostic marker in sepsis.
Has translational research delivered new drugs thus far?
Whereas there have been successes in drug development, most recently in the treatment of hepatitis C [37 ] and chronic myeloid leukaemia [38 ] , translational research is yet to deliver novel drugs to the clinic across all specialties. Indeed, recent advances in critical care have increasingly focussed on process of care and application of existing evidence [39 ] . In common with sildenafil, it is probable that, for the foreseeable future, drug discovery in critical care will derive from established therapies with alternative clinical indications; the emergence of hydroxymethylglutaryl-CoA-reductase inhibitors as a therapeutic option in ALI is one recent example of this approach.
Having shown promise as an anti-inflammatory therapy in both in-vitro and animal in-vivo lipopolysaccharide (LPS) models of ALI [40] [41] [42] the effect of pretreatment with simvastatin was studied in healthy volunteers exposed to inhaled lipopolysaccharide. Compared with untreated controls, the group treated with simvastatin demonstrated a reduction in neutrophil numbers and activity in the alveolar space, and a reduction in cytokines in BALF [43] . These data led to the initiation of the HARP study, a proof-of-concept placebo-controlled trial of simvastatin 80 mg in patients within 48 h of the onset of established ALI (n ¼ 60) [44 ] . The statin-treated group showed improvements in nonpulmonary organ dysfunction. In addition, modest improvements in pulmonary function were observed in patients who were still ventilated at 14 days, although these just failed to reach statistical significance. This was associated with an early reduction in pulmonary and systemic markers of inflammation. There was no difference in adverse events.
The HARP-2 study is currently underway, following a similar protocol to HARP but statistically powered to detect a difference in ventilator-free days between the treatment and control groups [clinical trial registered with www. controlled-trials.com (ISRCTN88244364)].
What can translational research deliver over the next 10 years?
On the basis of the emerging data presented in this brief review, it is clear that the critical care community is beginning to adopt an increasingly translational approach to research, drug development and early-phase clinical trials. The focus of the next decade will be to bring validated and qualified biomarkers to the clinic; through improved patient characterization and more appropriate targeting of interventions in early-phase clinical trials, novel therapies should eventually be translated into clinical benefit. However, beyond biomarker development, what can translational research deliver?
The current solution to the limitation of patient heterogeneity in clinical trials is to undertake expensive, massive multicentre trials exemplified by the Australian and New Zealand Intensive Care Society Clinical Trials Group and Canadian Critical Care Trials Group [45] . Translational research additionally encompasses the use of computational analyses and adaptive study designs (such as Bayesian approaches) to optimize the design of early and late-phase clinical trials. One recent example of a sequential design was the recently completed trial comparing norepinephrine and dopamine for patients with shock [46 ] . Detractors argue that such study designs may lead to an increased possibility of a false-positive trial. However, the future application of such methodologies, combined with biomarker-based phenotyping of enrolled patients in a collaborative industry and academia study could dramatically reduce the number of patients required to power studies whilst potentially reducing the need for confirmatory studies.
Pharmacogenomics, the use of genotyping to inform drug prescribing, is gaining increasing exposure in the scientific literature [47 ,48 ,49 ] . Pharmacogenomic profiling of patients on intensive therapy unit (ITU) admission could provide valuable information relating to drug metabolism (e.g. cytochrome p450 isoenzymes), excretion and toxicity that would guide antibiotic choice and dosing schedules, for example, contributing to patient safety on the ITU particularly in patients with organ failures that dramatically affect pharmacokinetics. So-called P4 (personalized, preventive, participatory, and predictive) medicine is driven by the advent of novel high-throughput DNA screening methods [50 , 51, 52] , which could allow genome-wide sequencing for less than the cost of a day's intensive care stay [53 ] . The ultimate goal of such an approach would be to combine evidencebased clinical decision-making with a systems biology approach to select treatments of greatest benefit and least harm based on unique patient characteristics (Fig. 4) [54] .
Establishing comprehensive biobanks containing specimens linked to robust clinical information enabling precise phenotyping and including outcomes will allow a much broader assessment of the clinical importance of genetic variation across a range of critical illness, further informing future study and accurate phenotyping of patients for clinical trials. In addition, some previously failed therapies may in the future be found to be well tolerated and effective when applied to subgroups of patients defined by specific genetic, transcriptomic or metabonomic markers.
Historically, the majority of industrial collaborations in critical care have been limited to pharma-sponsored clinical trials. However, the adoption of a more translational approach to future research will attract and demand industrial partners. Collaborations between research institutions and industry allow the traditional strengths of the two to be pooled. Pharmaceutical companies have limited access to patients and clinical samples in addition to a limited working knowledge of the array of technologies at the disposal of intensivists. Researchers, on the contrary, would benefit from industry's considerable expertise in trial design, recruitment and clinical data monitoring; access to high-throughput technologies and vast banks of novel targets and therapies; and significantly greater research budgets (Fig. 3) .
Despite the undoubted promise of translational research methodologies and technologies in critical care research, enthusiasm for their revolutionary potential should be tempered by limitations of current translational science within the environment of critical care (Table 1) . Whereas there is reason to be optimistic about the potential of statins and other emerging drugs, it is important to interpret these studies in the context of the recent latephase failure of beta-agonists as a therapy in ALI. Despite promising preclinical data and a small randomized clinical trial demonstrating improvements in extravascular lung water at day 7 [55] , two recent large multicentre trials of beta-agonists l in ALI have been terminated early due to interim analysis suggesting a low likelihood of a positive outcome [56, 57 ] . Validation of diagnostic biomarkers requires comparison with a 'gold standard' investigation; diagnosis of syndromes such as ALI and sepsis currently rely on clinical acumen for confirmatory diagnosis. In addition, whereas validated biomarkers are emerging in AKI, there has been relatively little independent analysis of the validity of the tests used to identify the markers in biologic specimens. It will continue to be logistically challenging to take full advantage of emerging technologies including 
Targeted therapy
Initial assessment will always demand a thorough history and examination but validated biomarkers will assist in both diagnostic confirmation and risk assessment early in the clinical course. Once a diagnosis is confirmed pharmacogenomic markers will stratify patients in to relevant treatment groups while accurate phenotyping and selection of likely 'responders' will optimize the outcome of future clinical trials. Adapted from Trusheim et al. [54] .
PET and fMRI in critical care, whereas the practicalities (including consent) of tissue sampling will always be problematic. Finally, interpretation of the complex data generated by '-omics' technologies, particularly genomic data, can be challenging [58 ] .
Conclusion
Over the past decade tremendous advances in the ability to detect and measure the genes, proteins and metabolites involved in critical illness have been developed. To date, there has been little direct impact on the therapeutic interventions available to clinicians. However, the rapidity with which these early data have accumulated allied to anticipated advances in bioinformatics and systems biology will hopefully provide meaningful advances in critical care therapeutics over the next decade. In the meantime, new understanding of inflammatory mediators and pathways, immunity, and genetic variability in critical illness will further inform and enhance the search for appropriate biomarkers, which in turn will allow accurate phenotyping of patients enrolled in future clinical trials. The key to the success of this process will inevitably require positive collaboration between academia, critical care clinicians and industrial partners. 
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